News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,070 Results
Type
Article (41599)
Company Profile (463)
Press Release (659008)
Section
Business (208396)
Career Advice (2002)
Deals (35941)
Drug Delivery (92)
Drug Development (83315)
Employer Resources (169)
FDA (16330)
Job Trends (15043)
News (352105)
Policy (32984)
Tag
Academia (2620)
Alliances (50601)
Alzheimer's disease (1273)
Approvals (16255)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11732)
Biotechnology (349)
Breast cancer (123)
Cancer (1109)
Cardiovascular disease (102)
Career advice (1671)
Cell therapy (247)
Clinical research (66000)
Collaboration (404)
Compensation (199)
COVID-19 (2590)
C-suite (100)
Data (1136)
Diabetes (156)
Diagnostics (6196)
Earnings (86042)
Employer resources (147)
Events (112914)
Executive appointments (313)
FDA (16870)
Funding (362)
Gene therapy (191)
GLP-1 (610)
Government (4408)
Healthcare (18996)
Infectious disease (2674)
Inflammatory bowel disease (113)
Interviews (308)
IPO (16571)
Job creations (3694)
Job search strategy (1428)
Layoffs (439)
Legal (7928)
Lung cancer (174)
Manufacturing (181)
Medical device (13324)
Medtech (13329)
Mergers & acquisitions (19430)
Metabolic disorders (423)
Neuroscience (1564)
NextGen Class of 2024 (6733)
Non-profit (4532)
Northern California (1494)
Obesity (242)
Opinion (198)
Patents (102)
People (57622)
Phase I (20681)
Phase II (29133)
Phase III (21548)
Pipeline (458)
Postmarket research (2590)
Preclinical (8878)
Radiopharmaceuticals (251)
Rare diseases (233)
Real estate (5998)
Regulatory (21961)
Research institute (2404)
Resumes & cover letters (351)
Southern California (1323)
Startups (3746)
United States (13800)
Vaccines (565)
Weight loss (182)
Date
Today (134)
Last 7 days (841)
Last 30 days (3838)
Last 365 days (36672)
2024 (33588)
2023 (41014)
2022 (52278)
2021 (56769)
2020 (54926)
2019 (47423)
2018 (35700)
2017 (33027)
2016 (32347)
2015 (38396)
2014 (32187)
2013 (27115)
2012 (29225)
2011 (29867)
2010 (27997)
Location
Africa (731)
Arizona (200)
Asia (38512)
Australia (6402)
California (3407)
Canada (1289)
China (250)
Colorado (146)
Connecticut (160)
Europe (83994)
Florida (458)
Georgia (116)
Illinois (351)
Indiana (198)
Kansas (99)
Maryland (588)
Massachusetts (2710)
Michigan (159)
Minnesota (277)
New Jersey (965)
New York (965)
North Carolina (754)
Northern California (1494)
Ohio (140)
Pennsylvania (847)
South America (1105)
Southern California (1323)
Texas (473)
Utah (92)
Washington State (371)
701,070 Results for "ptc therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene therapy Kebilidi for AADC deficiency. It is the first approved gene therapy to be delivered directly to the brain.
November 14, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
PTC Therapeutics to Participate at Upcoming May 2024 Investor Conference
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conference.
May 29, 2024
·
1 min read
Pharm Country
PTC Therapeutics Announces Validation of Sepiapterin European MAA
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.
May 28, 2024
·
6 min read
Press Releases
PTC Therapeutics to Participate at Upcoming Investor Conferences
November 4, 2024
·
1 min read
Pharm Country
PTC Therapeutics to Participate at Upcoming May 2024 Investor Conferences
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.
May 2, 2024
·
1 min read
Pharm Country
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency.
May 14, 2024
·
6 min read
Business
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024.
April 25, 2024
·
14 min read
Policy
PTC Therapeutics Provides Key Regulatory Updates
PTC Therapeutics, Inc. announced the submission of a BLA to the U.S. FDA for Upstaza™, a gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency.
March 19, 2024
·
8 min read
Pharm Country
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP’s negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation.
May 20, 2024
·
6 min read
Pharm Country
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 21, 2024
PTC Therapeutics, Inc. announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to nine new employees.
June 21, 2024
·
2 min read
1 of 70,107
Next
